Canada: Canadian Drug Price Review Of Generic Companies Holding Patents

Last Updated: October 8 2019
Article by Noel Courage and Nyrie Israelian

Generic drug companies typically do not have patents. Occasionally they may have patents on a new formulation of an old drug. Other times they may be operating under a license of another company’s patent. Either scenario can trigger Canadian price review.

The Patented Medicines Price Review Board (PMPRB) is an independent, quasi-judicial body with the mandate of ensuring that prices for patented medicines sold in Canada are not excessive. The PMPRB has jurisdiction to review price of any patented medicines, as long as a Canadian patent exists with the slenderest thread of connection to the medicine. Generic drugs makers should take note that recent case law and updates to PMPRB policies have made clear that the PMPRB’s jurisdiction extends to generic drugs as well. However generic companies are considered a low risk by the PMPRB and are not going to be required to make price filings with the Board, except upon request.

Generics can come within the definition of “patentees”

In Canada (Attorney General) v Sandoz Canada Inc, the Federal Court of Appeal (FCA) considered whether generic drug makers could be “patentees” subject to review under the excessive price provisions of the Patent Act1. The FCA found that an implied licence existed from the consent given by patent holders in order to allow Sandoz to cross-reference their medicine and obtain the required marketing authorization (called a Notice of Compliance (NOC))2.

The issue turned on the interpretation of the definition of “patentee.” This definition states that a “in respect of an invention pertaining to a medicine, means the person for the time being entitled to the benefit of the patent for that invention and includes, where any other person is entitled to exercise any rights in relation to that patent … that other person in respect of those rights”3.

The FCA found that the legislative purpose was not only preventing patent holders from pricing their patented medicines excessively (generic companies charge less than the brand name medicine)4. The FCA held that the mischief sought to be prevented could be caused without the patent owner itself charging excessive prices, and therefore a broader characterization of the legislative purpose was the correct interpretation5. Review of generic prices in this situation also withstood a constitutional challenge, and was found to be within federal jurisdiction.

Sandoz’s and Ratiopharm’s application for leave to appeal to the SCC was discontinued, and the FCA’s decision was subsequently followed in the FCA in Alexion Pharmaceuticals Inv v. Canada (Attorney General)6. As a result, the PMPRB has jurisdiction to control the prices charged by generic companies for patented medicines, when the patent owner or holder has given explicit or implied selling rights under a licence to the generic company.

Updates to the PMPRB’s policies on patented generic drugs

In February 2017, the PMPRB announced that it will be moving patented generic drug price reviews to a complaint-based process, similar to the provisions for new and existing veterinary and over the counter drug products7. In its updated policy on generic medicines, the stated rationale for this decreased regulatory burden was that patented generic drugs represent a potentially lower risk category of patented medicines, and therefore a lower priority for PMPRB regulatory investigation8. The Board staff will commence an investigation into the price of a patented generic drug if all three of the following conditions are met:

  1. a substantiated complaint has been received in respect of the patented generic drug;
  2. the patentee of the patented generic drug is the only company in Canada selling a generic version of the drug in Canada; and
  3. the patented generic drug is not the subject of a pricing agreement with the pan-Canadian Pharmaceutical Alliance (pCPA), to which it is compliant. The onus of proving to PMPRB staff that a patented generic drug is subject to, and compliant with, a pricing agreement with the pCPA will rest with the patentee for that patented generic drug.

Reduced Reporting Requirements - Amendments to the PMPRB Regulations

Forthcoming amendments to the PMPRB Regulations would reduce reporting obligations to patented generic medicines so that price, sales, and identity information would only be required on request by the PMPRB. According to the PMPRB, during the initial consultation on the proposed amendments to the Regulations, generic medicine industry representatives supported this amendment.

There Appears to be No Publicly Available Ongoing Enforcement Action Against A Generic Company

We reviewed the list of PMPRB of hearings. The only relevant matter before the Board is a failure to file issue with Apotex, but the PMPRB’s Application has been discontinued (it’s been ongoing since 2007, and the Sandoz and Ratiopharm cases settled the jurisdictional issues raised in the Application). We reviewed the settlements (called Voluntary Compliance Undertakings (VCU)) from 2016-2019, and saw no ‘patented generic’ drugs. It appears that generic company patentees need to be aware of potential for PMPRB price review, but not concerned about ongoing PMPRB administrative filings or undergoing regular scrutiny.


1 Canada (Attorney General) v Sandoz Canada Inc, 2015 FCA 249 [Sandoz 2]

2 Ibid at paras 103-108.

3 Patent Act,  RSC 1985, c P-4, s 79(1)

4 Supra note 1.

5 Ibid at paras 65-67.

6 Alexion Pharmaceuticals Inc v Canada (Attorney General), 2017 FCA 241.

7 Canada, Patented Medicine Price Review Board, PMPRB NEWSletter, vol 21 issue 1 (Ottawa: PMPRB, 2017), online: <>

8 Canada, Patented Medicine Price Review Board, Compendium of Policies, Guidelines and Procedures at B.8

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions